Pharmacoeconomic review report Migalastat (Galafold) (Amicus therapeutics)
Migalastat (Galafold) is indicated for the long-term treatment of adults with a confirmed diagnosis of Fabry disease (alpha-galactosidase A deficiency) who have an amenable mutation. The recommended dosage is 123 mg every other day at the same time of day. At the submitted price, migalastat at $1,70...
| Autor principal: | |
|---|---|
| Autor Corporativo: | |
| Formato: | Libro electrónico |
| Idioma: | Inglés |
| Publicado: |
Ottawa (ON) :
CADTH
2018.
|
| Colección: | Common drug review clinical review report.
|
| Materias: | |
| Ver en Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820269106719 |
| Sumario: | Migalastat (Galafold) is indicated for the long-term treatment of adults with a confirmed diagnosis of Fabry disease (alpha-galactosidase A deficiency) who have an amenable mutation. The recommended dosage is 123 mg every other day at the same time of day. At the submitted price, migalastat at $1,700 per capsule is $310,250 annually per patient, which is similar to the publicly available prices of IV enzyme replacement therapy (ERT). The indication for migalastat differs with the indication for ERTs, given the requirement for an amenable mutation for migalastat. |
|---|---|
| Descripción Física: | 1 online resource (30 pages) : illustrations |
| Bibliografía: | Includes bibliographical references. |
